Partnering with CD3

CD3 invests in your science, co-develops your discoveries and connects you to pharma so your research reaches patients

CD3 Capabilities

We invest in early-stage drug discovery projects, helping you navigate the complex path from lab discovery to clinical development. With CD3, you gain access to a dynamic research team, high-throughput screening, medicinal chemistry resources, and a vast network of pharmaceutical industry partners.

Drug discovery

CD3 focuses on the discovery of new and innovative small molecule drugs in collaboration with academic research groups or biotech (spin-off) companies by delivering financial means in combination with expert drug discovery support.

Co-creation & technical expertise

We offer a collaborative environment where you retain control and involvement in your project. Our expertise:

  • Assay development and/or optimization
  • High throughput screening
  • High quality diverse compound libraries for screening
  • Smaller focused libraries (e.g. kinase library, etc.)
  • In silico molecule design, modelling and screening
  • Medicinal chemistry
  • Organic synthesis
  • ADME-Tox evaluations
  • PK and in vivo efficacy evaluations
  • PD biomarker development and analysis
  • Antibody discovery
  • Project coordination and follow-up
  • Protection of intellectual property rights

Outlicensing & investments

I am text block. Click edit button to change this text. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.

The Partnership Process

By partnering with CD3, your research benefits from our financial resources, scientific expertise, and industry connections, increasing the likelihood of your discoveries reaching patients and making a real-world impact.

Initial Evaluation

  • Bullet 1
  • Bullet 2
  • Bullet 3
  • …

Incubation & development

  • Bullet 1
  • Bullet 2
  • Bullet 3
  • …

Outlicensing and spin-off

  • Bullet 1
  • Bullet 2
  • Bullet 3
  • …

Traditional funding vs. CD3’s partnership model

Aspect
Funding Source

Traditional Funding Model
Limited to grants, institutional funds

CD3’s Partnership Mode
Investment fund with 60+ million euros dedicated to drug discovery

Scientific Support

Limited or none

Access to experienced drug discovery team and high-throughput screening